Celcuity (CELC)

• Market cap: $463M
• 1 day: 3.83%
• 5 days: -0.48%
• 1 month: -2.50%
• 3 months: -16.09%
• 6 months: -19.97%
• Year to date: -15.70%
• 1 year: -13.59%
• 5 years: 25.86%
• 10 years: -12.81%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Employees: 55

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

159% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 17

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

14% more funds holding

Funds holding: 92 [Q2] → 105 (+13) [Q3]

10.65% less ownership

Funds ownership: 91.73% [Q2] → 81.08% (-10.65%) [Q3]

15% less capital invested

Capital invested by funds: $530M [Q2] → $450M (-$80M) [Q3]

78% less call options, than puts

Call options by funds: $504K | Put options by funds: $2.27M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $23 85% upside
• Avg. target: $31 146% upside
• High target: $42 237% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target	117% upside $27	Buy Reiterated	15 Nov 2024
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target	85% upside $23	Buy Reiterated	15 Nov 2024
Stifel Bradley Canino 21% 1-year accuracy 7 / 33 met price target	237% upside $42	Buy Maintained	7 Oct 2024